Phase II study of concurrent methotrexate and bleomycin chemotherapy.
D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008168:Lung / Q000187:drug effects; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D013997:Time Factors
D001761:Bleomycin; D008727:Methotrexate